Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pegvorhyaluronidase Alfa · PEGPH-20

Recombinant protein · Inhibitor of Hyaluronic acid · developed by Halozyme Therapeutics

Phase 1/2 Most advanced trial (none active)
HALO Developer
4 Registered trials

What is Pegvorhyaluronidase Alfa?

Pegvorhyaluronidase alfa is a pegylated recombinant form of human hyaluronidase that degrades hyaluronic acid coating tumor cells and in the extracellular matrix. It is being studied in pancreatic, lung, and gastric or esophageal adenocarcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PEGPH-20
Drug type
Recombinant protein
Targets
Hyaluronic acid
Mechanism
Inhibitor of Hyaluronic acid
Pathways
hyaluronic acid degradation, tumor interstitial fluid pressure reduction, chemotherapy penetration into tumors
Therapy area
Oncology
Developer
Halozyme Therapeutics (HALO)
Also in trials of
BLRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
P01I4980ZS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04134468 Phase 2 Pancreatic Ductal Adenocarcinoma Withdrawn HALO
NCT03281369 Phase 1/2 Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Terminated BLRX
NCT01959139 Phase 1/2 Metastatic Pancreatic Adenocarcinoma Completed HALO
NCT02346370 Phase 1 Non-small Cell Lung Cancer Terminated HALO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Pancreatic AdenocarcinomaNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HALO page.

Follow HALO, the company behind Pegvorhyaluronidase Alfa

See HALO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HALO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.